Search results for "Prednisone"

showing 8 items of 98 documents

Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results

2012

Abstract Abstract 1632 Background: OFA is a fully human monoclonal antibody that binds to both the large and small extracellular loops of CD20. OFA is currently approved for patients (pts) with refractory chronic lymphocytic leukemia and has demonstrated activity in non-Hodgkin's lymphomas, including follicular lymphoma (FL). We previously reported results of a phase II study of OFA in combination with CHOP (cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, prednisone 100 mg daily for 5 days) chemotherapy (O-CHOP) in pts with previously untreated FL (Czuczman et al. Br J Haematol. 2012;157:438). We now report updated efficacy, safety and pharmacokinetic (PK) follow-up…

medicine.medical_specialtyVincristineImmunologyFollicular lymphomaPhases of clinical researchCHOPOfatumumabBiochemistryGastroenterology03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternational Prognostic IndexPrednisoneInternal medicinemedicinebusiness.industryCell BiologyHematologymedicine.diseaseChemotherapy regimen3. Good healthSurgerychemistry030220 oncology & carcinogenesisbusiness030215 immunologymedicine.drug
researchProduct

Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sec…

2021

Summary Background Presenting symptoms of childhood cancers might mimic those of rheumatic diseases. However, the evidence available to guide differential diagnosis remains scarce. Preventing wrong or delayed diagnosis is therefore important to avoid incorrect administration of glucocorticoid or immunosuppressive therapy and worsening of prognosis. As such, we aimed to assess the prevalence and characteristics of presenting musculoskeletal manifestations in patients at cancer onset and to identify the factors that differentiate childhood malignancies with arthropathy from juvenile idiopathic arthritis. Methods We did a multicentre, cross-sectional study at 25 paediatric haemato-oncology cen…

medicine.medical_specialtybusiness.industryImmunologyArthritisCancerOdds ratioMusculoskeletal manifestationJuvenile idiopathic arthritismedicine.diseaseHistiocytosisRheumatologySettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAPrednisoneInternal medicineJoint painArthropathyMusculoskeletal manifestations childhood cancer juvenile idiopathic arthritismedicinechildhood cancerImmunology and AllergyDifferential diagnosismedicine.symptombusinessmedicine.drug
researchProduct

Enteric-coated mycophenolate sodium in the treatment of refractory pemphigus

2010

Background  One of the major goals of pemphigus therapy is to reduce the patient’s cumulative exposure to systemic corticosteroids. To investigate the efficacy of enteric-coated mycophenolate sodium (EC-MPS), 10 patients with active, refractory pemphigus vulgaris (PV) or foliaceous (PF) were treated with EC-MPS (1440 mg daily) and prednisone (75 mg daily) over 18 months. Observations  Following EC-MPS/prednisone therapy, disease progression was inhibited between days 30 and 45 in 9/10 patients (8 PV; 1 PF). At 18 months, 8/9 PV patients had clinically quiescent disease; EC-MPS therapy was no longer required in two patients as a result of disease remission. The remaining PV patient showed no…

medicine.medical_specialtybusiness.industryPemphigus vulgarisMycophenolate SodiumAzathioprineDermatologymedicine.diseaseGastroenterologySurgeryPemphigusRefractoryPrednisoneInternal medicinemedicineAdjuvant therapyAdverse effectbusinessmedicine.drugInternational Journal of Dermatology
researchProduct

FRI0044 Non-steroidal anti-inflammatory drugs are more beneficial than anti-tnfα drugs on the radiographic damage in arthritis: a study in adjuvant i…

2017

Background The management of the chronic inflammatory rheumatisms has dramatically evolved in the last decade with a concept of “treat to target”. The theory of a window of opportunity with more beneficial effects of an early intensive treatment is supported by several evidences. The positive impact of an early treatment with a TNFα blocker is expected but the place and the interest of non-steroidal anti-inflammatory treatments (NSAIDs) and glucocorticoids is not clear. Objectives The aim of this study was to evaluate the radiological outcomes after an early treatment during 21 days by Etanercept, or Naproxene, or Celecoxib, or Prednisone, or Diclofenac or Methotrexate in adjuvant induced a…

medicine.medical_specialtybusiness.industrymedicine.medical_treatmentArthritisSystemic inflammationmedicine.diseaseGastroenterologyEtanerceptDiclofenacPrednisoneInternal medicinemedicineCelecoxibMethotrexatemedicine.symptombusinessAdjuvantmedicine.drugPoster Presentations
researchProduct

Enzymatic Determination in Serum of Lathyritic and Prednisone-treated Lathyritic Rats

1966

WHILE a remarkably raised serum-level of transaminases and aldolase is found in dermatomyositis, such augmentation, as a rule, is not found in cases of severe muscular involvement of scleroderma and disseminated lupus erythematosus (acutus)1–3.

medicine.medical_specialtyeducationLathyrismFructose-bisphosphate aldolaseSclerodermachemistry.chemical_compoundimmune system diseasesPrednisoneFructose-Bisphosphate AldolaseInternal medicinemedicineAnimalsAspartate Aminotransferasesskin and connective tissue diseasesCyanidesMultidisciplinaryL-Lactate DehydrogenasebiologyLathyrismbusiness.industryAldolase AAlanine TransaminaseAminopropionitrileDermatomyositismedicine.diseasehumanitiesRatsEndocrinologyAlanine transaminasechemistryAminopropionitrilebiology.proteinPrednisonebusinessmedicine.drugNature
researchProduct

Reversible Myelofibrose bei angioimmunoblastischer Lymphadenopathie

2008

Ankle oedema and abdominal swelling suddenly developed in a 55-year-old woman who also had lymphadenopathy in the neck, axillae and groin. Ultrasonography demonstrated hepatosplenomegaly, ascites and pleural effusions. Histological examination of some lymph-nodes from the axilla and groin revealed angioimmunoblastic lymphadenopathy (low-malignant peripheral T cell lymphoma). Bone-marrow biopsy was undertaken because of a normocytic anaemia (haemoglobin 4.9 g/dl) requiring blood transfusion, thrombocytopenia (5000/microliters) and monoclonal IgG gammopathy. This showed lymphoma-associated secondary myelofibrosis. Treatment with prednisone (2 mg/kg daily for 8 weeks) and vincristine (1 mg/m2 …

medicine.medical_specialtymedicine.diagnostic_testGroinbusiness.industryHepatosplenomegalyGeneral Medicinemedicine.diseaseGastroenterologyPeripheral T-cell lymphomamedicine.anatomical_structurePrednisoneGammopathyInternal medicineBiopsyAscitesmedicinemedicine.symptomMyelofibrosisbusinessmedicine.drugDMW - Deutsche Medizinische Wochenschrift
researchProduct

The Inhibitory Effects of Prednisone, 16-Methylen-Prednisolone, and Acth on Con-A Induced Lymphokines (Interferon-Y) as Measured by the Chemiluminesc…

1988

When lymphocytes are stimulated with mitogens or antigens they are enhanced via a cascade of lymphokines to produce interferon-y (IFN-y). IFN-y augments the H2O2 secretion of human monocytes which indirectly can be measured by chemiluminescence. We tested prednisone, 16-methylen-prednisolone and ACTH for their effect to inhibit the Con-A induced stimulation of the chemiluminescence-activity. All three hormones inhibited significantly the stimulation: prednisone up to 52.5% (concentration = 150 micrograms/ml, p = 0.000005), 16-methylen-prednisolone up to 22.5% (concentration = 2.5 micrograms/ml, p = 0.006) and ACTH up to 33% (concentration = 10 micrograms/ml, p = 0.0036).

medicine.medical_specialtymedicine.drug_classPrednisoloneImmunologyDose-Response Relationship ImmunologicStimulationAdrenocorticotropic hormoneToxicologyMonocytesInterferon-gammaAdrenocorticotropic HormoneInternal medicineConcanavalin AmedicineHumansImmunology and AllergyInterferon gammaPharmacologybiologybusiness.industryMonocyteLymphokineHydrogen PeroxideGeneral Medicinemedicine.anatomical_structureEndocrinologyConcanavalin ALuminescent Measurementsbiology.proteinPrednisolonePrednisoneCorticosteroidbusinessmedicine.drugImmunopharmacology and Immunotoxicology
researchProduct

OP0015 Induction of remission and maintenance in early, aggressive rheumatoid arthritis using adalimumab in combination with methotrexate with or wit…

2017

Background Remission is the current aim of early RA treatment. In patients with early, aggressive RA, combination with adalimumab (ADA) plus methotrexate (MTX) was superior to either MTX or ADA alone in obtaining clinical remission. Moreover, it has been demonstrated that a short-term aggressive treatment with high-dose glucocorticoids (GC) plus conventional DMARDs lead to long-term (up to 5 years) benefits. Objectives To compare the proportion of patients who achieve remission at 12 months, between two groups of subjects treated with ADA + MTX + high dose GC (intensive) and ADA + MTX + placebo (standard), and to evaluate the proportion of those maintaining remission at 24 months, after dis…

musculoskeletal diseasesmedicine.medical_specialtybusiness.industry030503 health policy & servicesmedicine.diseasePlaceboGastroenterologyDiscontinuationFirst line treatmentDouble blind study03 medical and health sciences0302 clinical medicineimmune system diseasesPrednisoneRheumatoid arthritisInternal medicinemedicineAdalimumabMethotrexate030212 general & internal medicine0305 other medical sciencebusinessmedicine.drug
researchProduct